Lexeo Therapeutics, PXV Funds and venBio launch new entity to advance RNA therapies for cardiac diseases
Ella Day | June 27, 2025 | News story | Mergers and Acquisitions, Research and Development | Cardiology, Lexeo Therapeutics, PXV Funds, RNA-based therapies, cardiac genetic medicine, venBio Partners
Lexeo Therapeutics has announced a strategic partnership with life sciences investors Perceptive Xontogeny Venture Funds (PXV Funds) and venBio Partners to launch a new company focused on developing RNA-based therapies for genetic cardiac diseases. Backed by up to $40m in private equity financing, the initiative aims to target conditions that current viral vector platforms, such as adeno-associated virus, are unable to treat effectively.
The new entity will leverage Lexeo’s expertise in cardiac genetic medicine, including preclinical intellectual property and technology, combined with a new non-viral RNA delivery platform. The goal is to develop therapeutics for patients with inherited cardiovascular diseases, a market currently valued at $13bn and projected to reach nearly $40bn by 2033.
“This partnership reflects an innovative approach to realise the therapeutic and economic value of promising preclinical science,” said R Nolan Townsend, CEO of Lexeo. “RNA therapeutics mediated by non-viral delivery represent the future of genetic medicine.”
In return for its contributions, Lexeo has secured a double-digit equity stake in the new entity, along with future milestone payments, royalties and opt-in rights to selected programmes.
“This collaboration brings together the right expertise and strategy to drive forward innovation in cardiac RNA therapeutics,” said Fred Callori, managing director at PXV Funds.
Corey Goodman, managing partner at venBio, added: “Lexeo’s leadership in the field will be key to transforming treatment for patients with serious cardiac conditions.”
Ella Day
27/6/25
